Home > Cardiology > ACC 2019 > Interventional Cardiology > TAVR superior and non-inferior to SAVR in low-risk patients

TAVR superior and non-inferior to SAVR in low-risk patients


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ACC 2019
Trial
PARTNER 3, Evolut Low Risk
Two landmark trials comparing transcatheter aortic valve replacement (TAVR) with surgical aortic valve replacement (SAVR) in low-risk patients have shown promising results. The PARTNER 3 trial demonstrated that TAVR was superior to SAVR with regard to the reduction of death, stroke, or rehospitalisation at 1 year [1]. Results from the Evolut Low Risk trial showed that TAVR with the self-expanding CoreValve was non-inferior to SAVR [2]. The randomised, parallel PARTNER 3 trial aimed to evaluate TAVR compared with SAVR in low-risk patients with symptomatic severe aortic stenosis. A total of 1,000 patients were enrolled in the study with a median follow-up of 1 year. Mean patient age was 73 years, 30% of patients was female, and 31% had diabetes mellitus. The mean Society of Thoracic Surgeons (STS) risk score was 1.9% (score <4% denoted ‘low-risk’, with higher scores indicating a greater risk of death within 30 days after surgery). The inclusion and exclus...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on